When you hear the phrase “biliary tract cancer”, most people have never heard of this deadly disease. Unlike lung cancer, breast cancer or colorectal cancer that get widespread public attention, biliary tract cancer (BTC) flies under the radar—but its threat to human life is just as severe, if not worse. Every year, thousands of patients around the world receive a devastating BTC diagnosis, and the majority of them learn their tumors are already too advanced for curative surgery at the time of detection. For decades, standard drug treatments have offered limited survival gains, leaving patients and their families with slim hopes for long-term recovery.
But a brand-new clinical trial launched by Peking University Cancer Hospital is rewriting this bleak outlook. This study tests a groundbreaking dual treatment strategy: combining hepatic arterial infusion chemotherapy (HAIC) with full-body systemic therapy, plus a flexible “de-escalation” treatment plan tailored to tumor response. The trial aims to shrink aggressive bile duct and gallbladder tumors dramatically, turn inoperable cancers into resectable ones, and extend patients’ lifespans far beyond what traditional chemotherapy can achieve. This article will break down everything you need to know about biliary tract cancer, why old treatments fall short, how HAIC works as a game-changing local therapy, what this new combined treatment entails, and what this ongoing clinical trial means for BTC patients globally—all explained in plain, jargon-free language for anyone without a medical background.
Part 1: What Exactly Is Biliary Tract Cancer, and Why Is It So Dangerous?
The Biliary System: Your Body’s Hidden “Bile Transport Pipeline”
To understand BTC, we first need to grasp the job of the biliary tract. Your liver constantly produces bile, a fluid that breaks down fats during digestion. The biliary tract acts as an interconnected network of thin tubes that carry bile from the liver to the gallbladder (which stores extra bile) and then into the small intestine. The entire system includes three key parts where cancer most often develops:
- Intrahepatic cholangiocarcinoma (iCCA): Tumors growing inside the bile ducts within the liver itself
- Perihilar cholangiocarcinoma (pCCA): Cancers at the junction where liver bile ducts merge before entering the gallbladder
- Gallbladder cancer (GBC): Malignancies forming on the wall of the gallbladder organ
These three subtypes fall under the broad umbrella term biliary tract cancer, or BTC for short. Unlike slow-growing, low-risk cancers such as early-stage prostate cancer, BTC is defined by two terrifying traits: extreme heterogeneity and high aggressiveness. Simply put, no two BTC tumors behave the same way, and almost all of them spread rapidly if left untreated.
Why Most BTC Diagnoses Come Too Late
The biliary tract sits deep inside your abdomen, with no nerve endings that trigger obvious pain in early disease stages. Early BTC causes vague, easy-to-miss symptoms: mild fatigue, slight loss of appetite, occasional dull abdominal discomfort, or minor jaundice (yellowed skin/eyes) that many people brush off as a temporary liver upset or gallstones. By the time severe, unignorable symptoms emerge—constant weight loss, persistent itching, severe jaundice, and sharp belly pain—the cancer has already advanced in over 80% of patients.
Surgery remains the only treatment that can fully cure BTC. Yet only roughly 20% of all newly diagnosed patients qualify for curative surgical resection. The rest face unresectable (inoperable) tumors: either the cancer has spread to multiple liver regions, invaded major blood vessels, or formed limited distant metastases that rule out complete surgical removal.
The Grim Survival Stats of Unresectable BTC
For patients stuck with inoperable biliary tract cancer, the historical prognosis is devastating. Before modern drug combinations hit the market, the average overall survival (OS)—the length of time patients live after diagnosis—clocked in at less than six months. Even after decades of chemotherapy development, traditional treatments still deliver modest benefits at best.
For many years, the gold-standard first-line treatment for unresectable BTC was a two-drug chemo pair: gemcitabine plus cisplatin, shortened to GemCis. This regimen barely moved the needle on tumor control: only 26.1% of patients saw their tumors shrink significantly (this metric is called objective response rate, or ORR), and the median overall survival stayed under one full year. Patients would undergo regular IV chemo, yet their tumors kept progressing quickly for most recipients.
Around 2022, two landmark global phase III clinical trials (TOPAZ-1 and KEYNOTE-966) brought a small breakthrough by adding immune checkpoint inhibitors to GemCis chemotherapy. Immune drugs like durvalumab and pembrolizumab wake up the body’s own immune cells to attack cancer cells, working alongside chemo to boost anti-tumor power. These trials pushed median survival up to 12.9 months and 12.7 months respectively, and all major global cancer guidelines updated their recommendations to prioritize this chemo-immunotherapy combo for unresectable BTC.
Still, the progress left much to be desired. Even with added immunotherapy, the ORR only climbed to 26.7%–29%. Fewer than one in three patients experienced meaningful tumor shrinkage, and most patients’ cancers continued to advance within a year of starting treatment. Doctors worldwide recognized a critical unmet medical need: we required a more powerful therapy that could drastically shrink BTC tumors and deliver longer survival for more patients. That gap is where HAIC stepped into the spotlight.
Part 2: Hepatic Arterial Infusion Chemotherapy (HAIC): The Local Treatment That Transforms BTC Care
How HAIC Differs From Standard Intravenous Chemotherapy
Nearly all traditional chemo and immunotherapy are systemic treatments: drugs are injected into a vein in your arm, flow through your entire bloodstream, and circulate across every organ in your body. While this lets medication reach cancer cells that have spread distantly, it creates two major drawbacks:
- Only a tiny fraction of the chemo drug actually reaches liver-based BTC tumors; most medicine disperses into healthy tissues across the body.
- High drug doses are required to hit tumor targets, which triggers widespread side effects: hair loss, severe nausea, bone marrow suppression, fatigue, and organ irritation.
HAIC, or hepatic arterial infusion chemotherapy, flips this delivery model on its head with a targeted, local approach. Surgeons place a thin, tiny catheter directly into the hepatic artery—the blood vessel that supplies nearly all oxygen and nutrients to liver tumors. Chemotherapy drugs are pumped slowly and continuously through this catheter straight into the tumor’s blood supply.
This targeted delivery creates two massive advantages over regular IV chemo:
- Tumor tissue gets extremely high concentrations of anti-cancer medication, maximizing cell-killing effects on BTC lesions.
- Far less chemo leaks into healthy organs outside the liver, cutting down on systemic side effects drastically.
The result? HAIC consistently achieves far higher tumor shrinkage rates than standard systemic chemo alone, with ORR repeatedly hitting 50% to 60% across published clinical studies. For BTC patients with large, multi-lesion liver tumors, this local treatment delivers a powerful blow to the primary cancer mass that full-body drugs cannot match.
Real-World Clinical Proof: HAIC Outperforms Standard Chemo for All BTC Subtypes
Over the past decade, dozens of retrospective and prospective clinical studies have confirmed HAIC’s superiority for every major form of biliary tract cancer, with standout data that shocked hepatobiliary oncologists:
Intrahepatic Cholangiocarcinoma (iCCA)
iCCA tumors grow within the liver and often develop multiple separate lesions, making surgical removal extremely difficult. A 2022 multi-center study compared 141 HAIC patients and 178 patients who received surgical resection. The median overall survival for the HAIC group hit 20.3 months, versus 18.9 months for surgery patients—statistically nearly identical survival outcomes. Considering liver resection carries major risks of post-surgical complications, HAIC emerged as a viable, gentler alternative for patients with multifocal iCCA unsuitable for major liver surgery.
A 2024 head-to-head trial delivered even more eye-opening results for locally advanced inoperable iCCA. Researchers split patients into two groups: one receiving HAIC, the other standard GemCis systemic chemo. The HAIC group actually had heavier tumor burden (73.4% with multiple liver lesions, compared to just 55.3% in the chemo group). Even with worse baseline disease, HAIC patients saw median survival jump to 27.7 months—more than double the 11.8 months recorded in the GemCis arm.
Perihilar Cholangiocarcinoma (pCCA)
For pCCA, tumors block central bile ducts and often cause severe jaundice, with limited response to systemic therapy. A single-center phase II trial run at Peking University Cancer Hospital in 2017 tested HAIC using oxaliplatin plus fluorouracil drugs. The treatment yielded an ORR of 67.6%, median progression-free survival (PFS, time before tumors start growing again) of 12.2 months, and median OS of 20.5 months—numbers far above any standard systemic regimen available at that time.
Gallbladder Cancer (GBC)
Gallbladder cancer is widely considered the most aggressive BTC subtype, with rapid spread and poor treatment response. A 2021 retrospective analysis from the same Peking University team looked at 26 advanced GBC patients treated with HAIC. Nearly a quarter of these patients had already failed prior systemic chemo, and over one-third could not tolerate standard full-body drug therapy at all. HAIC still delivered incredible results: median PFS of 10 months, median OS of 13.5 months, ORR of 69.2%, and a disease control rate (DCR, meaning tumors stopped growing or shrank) of 92.3%. Over nine out of ten patients gained stable or reduced tumor volume with HAIC alone.
The Extra Power of Combining HAIC + Systemic Therapy
While HAIC alone works wonders on liver-based primary tumors, it cannot fully target tiny cancer cells that have drifted to distant organs outside the liver. Systemic chemo, immunotherapy, and anti-angiogenesis drugs (medicines that cut off blood flow feeding tumors) excel at eliminating these scattered metastatic cells. This logical pairing sparked a wave of combination therapy research that proved HAIC plus systemic treatment creates a synergistic effect—meaning the two therapies work better together than either could alone.
A 2022 phase II trial tested HAIC with floxuridine alongside systemic gemcitabine and oxaliplatin (GEMOX) for unresectable iCCA. The combined regimen produced median PFS of 11.8 months, median OS of 25 months, an 84% six-month disease control rate, and partial tumor shrinkage in 58% of participants. Most impressively, the Peking University team published 2025 phase II data for HAIC plus bevacizumab (anti-blood vessel drug) and toripalimab (PD-1 immune inhibitor). This triple combination hit an ORR of 84.38%—more than three times the response rate of traditional GemCis immunotherapy. Many participants’ tumors shrank so drastically that surgeons could perform curative resection afterward, with post-operative pathology confirming complete elimination of cancer tissue in some lesions.
This mountain of positive clinical data laid the foundation for the new trial. Doctors now knew HAIC + systemic therapy could drive massive tumor shrinkage, but one critical question remained unanswered: how can we adjust treatment intensity safely once patients respond well to therapy? This gap birthed the trial’s core innovation: the de-escalation strategy.
Part 3: Inside the New Peking University Clinical Trial
Core Trial Concept & Launch Timeline
Officially titled “HAIC Combined With Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer: A Conceptual Study”, this interventional clinical trial is led by Peking University, with treatment taking place at Peking University Cancer Hospital in Beijing, China. The trial officially opened for patient enrollment on March 31, 2026, and remains actively recruiting participants as of mid-2026. Researchers estimate primary study data collection will wrap up in March 2028, with full trial completion by March 2029. Around 40 BTC patients total will join the study, split into two separate experimental groups based on their cancer stage.
Unlike many rigid clinical trials that lock patients into identical treatment cycles from start to finish, this study’s unique selling point is its flexible de-escalation framework. The word “de-escalation” simply means stepping down treatment intensity once patients achieve strong tumor responses, to avoid unnecessary side effects while preserving long-term disease control.
Two Patient Groups Tailored to Cancer Stage
All participants are split into two arms, both receiving HAIC plus systemic therapy combinations with slight drug adjustments based on whether their cancer is locally advanced or widely advanced:
- Locally Advanced BTC Group
Patients whose tumors have not spread far outside the liver receive HAIC with the GOLF drug cocktail (gemcitabine, oxaliplatin, fluorouracil) delivered via hepatic artery catheter. They also get two systemic infusions every 3–4 weeks: bevacizumab and a PD-1/PD-L1 immune checkpoint inhibitor. Once scans show tumors shrink completely (complete response, CR), partially (partial response, PR), or stop growing (stable disease, SD), doctors shift patients to de-escalation care: either curative local therapy (surgical resection, tumor ablation, SIRT or SBRT radiation) or long-term maintenance oral/IV medication (S-1 chemo, bevacizumab, and immune inhibitor). If tumors begin growing again (progressive disease, PD), patients switch to second-line rescue treatments. - Advanced BTC Group
Patients with more widespread tumor spread receive a modified HAIC FOLFOX regimen (oxaliplatin + fluorouracil) instead of GOLF. Their systemic therapy package adds gemcitabine alongside bevacizumab and PD-1/PD-L1 inhibitor, administered every 3–4 weeks. The exact same de-escalation and second-line rescue rules apply as the locally advanced group. Key Goals the Trial Aims to Measure
Researchers track two primary main outcomes over up to 36 months of follow-up for every patient: - Overall Survival (OS): Total time from starting treatment until death from any cause—the gold standard metric for measuring whether a therapy extends patients’ lives.
- Clinical Complete Response Rate: The percentage of patients whose tumors disappear entirely on imaging scans at any point during treatment, judged using standard mRECIST tumor measurement guidelines used worldwide in cancer trials.
Secondary secondary endpoints capture equally vital data:
- Progression-Free Survival (PFS): How long patients live without their tumors growing or spreading
- Objective Response Rate (ORR): Share of patients with either full tumor disappearance or major shrinkage
- Safety Profile: Number of participants experiencing treatment-related side effects, graded by the universal CTCAE v5.0 toxicity scale, including mild, moderate and severe adverse events. Who Can Join the Trial? Basic Eligibility Rules
To qualify for enrollment, candidates must meet straightforward inclusion criteria: - Age range 18 to 80 years old, all genders welcome
- Biopsy-confirmed BTC (intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, gallbladder cancer)
- No widespread distant metastases, or only limited isolated metastatic lesions
- No prior chemotherapy, immunotherapy or targeted cancer treatment (treatment-naive)
- Good daily function level (ECOG performance score below 2)
- Moderate or healthy liver function (Child-Pugh Class A or B liver score ≤7)
- Healthy blood cell counts, albumin, kidney function, and normal blood clotting markers
People cannot join the trial if they carry exclusion factors such as other concurrent cancers, distal cholangiocarcinoma, allergies to platinum chemo or contrast dye, pregnancy/lactation, multiple distant metastases with malignant fluid buildup in chest or abdomen, prior organ transplants, active untreated infections, or severe uncorrectable blood clotting disorders.
Part 4: Why This Trial Represents a Turning Point for BTC Patients
Solving Two Major Flaws of Current BTC Treatment
Standard first-line BTC immunochemotherapy suffers from two critical limitations this trial directly addresses: weak tumor shrinkage and long-term toxic burden.
First, low ORR means most patients never get a chance at curative surgery. HAIC’s high local drug concentrations drastically boost tumor shrinkage odds, converting more inoperable tumors into resectable disease—offering patients a shot at potential long-term remission.
Second, indefinite high-intensity combination therapy causes cumulative side effects that wear patients down over months or years. The de-escalation strategy built into this trial is a patient-centered innovation: once tumors are well-controlled, harsh multi-drug HAIC cycles stop, replaced with gentler maintenance drugs or one-time curative local treatments. Patients retain anti-cancer protection while cutting down on fatigue, nausea, blood count drops and other taxing side effects.
Broader Global Implications for Biliary Tract Cancer Care
If this trial delivers positive results, it will rewrite clinical practice guidelines for unresectable BTC across the globe. Currently, doctors worldwide rely solely on systemic immunochemotherapy as frontline care. This study will provide robust prospective evidence supporting HAIC plus systemic therapy as a superior first-line option, with a sustainable step-down treatment model that balances efficacy and quality of life.
For patients in low- and middle-income countries where access to expensive long-term immunotherapy is limited, the de-escalation framework also offers economic benefits: after initial intensive HAIC combination treatment, many patients will move to cheaper oral maintenance drugs instead of endless expensive IV immune infusions.
Hope for Patients Who Previously Had Few Options
Thousands of BTC patients every year hear doctors say their tumors cannot be removed surgically, with standard treatments only offering roughly one year of median survival. This new HAIC combination trial builds on years of promising retrospective and phase II data that doubled or tripled survival times for many participants. Even patients who failed prior systemic therapy showed meaningful tumor responses to HAIC in earlier studies, meaning this approach could eventually help second-line patients too if later trial expansions prove successful.
Crucially, the trial originates from China, a country with one of the highest global incidence rates of cholangiocarcinoma and gallbladder cancer. Research from Peking University fills a vital gap in Asian BTC clinical data, which has historically been underrepresented in large Western-led global trials. The results will be especially relevant for Asian patients, who carry distinct risk factors and tumor biology compared to Western populations.
Part 5: Looking Forward – What Comes Next After This Trial
The study is classified as a conceptual exploratory trial with a small planned enrollment of 40 participants, designed to collect initial safety and efficacy data to validate the de-escalation HAIC-systemic therapy model. If the data shows strong ORR, improved OS and manageable side effects, researchers will launch larger, randomized phase II and phase III trials comparing this new regimen head-to-head against the current global standard GemCis plus immunotherapy.
If those larger trials confirm superior survival outcomes, pharmaceutical and clinical bodies will push to register HAIC combination therapy as an official first-line standard of care for unresectable locally advanced and advanced BTC. Beyond initial treatment, the de-escalation framework may be adapted for other liver-based malignancies, such as hepatocellular carcinoma (liver cancer), expanding HAIC’s utility across multiple gastrointestinal cancer types.
For individual patients awaiting new treatment options, this ongoing trial offers a potential path to better disease control at Peking University Cancer Hospital in Beijing. The trial’s lead investigator, Dr. Xiaodong Wang, accepts inquiries from eligible BTC patients and their families via phone or email for screening assessments to determine trial eligibility.
Conclusion
Biliary tract cancer has long stood as one of the most devastating, underserved malignancies in oncology, with limited effective treatments and dismal survival statistics for inoperable patients. For over a decade, hepatic arterial infusion chemotherapy has quietly demonstrated extraordinary tumor-shrinking power across all BTC subtypes, outperforming standard full-body chemo in dozens of clinical studies. By pairing HAIC’s targeted local anti-tumor punch with systemic immunotherapy and targeted drugs that hunt distant microscopic cancer cells, doctors at Peking University have created a synergistic treatment cocktail far more potent than any single therapy alone.
Related Clinical Trials
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoD07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoClinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This trial is a single-agent, single-arm, multicenter, open-label design clinical trial for advanced intrahepatic cholangiocarcinoma who have failed standard therapy. To evaluate the efficacy of VG161 administered by ultrasound or CT-guided intratumoral injection in patients with advanced intrahepatic cholangiocarcinoma, with the primary outcome measure being objective response rate (ORR).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study Comparing BL-B01D1 With Treatment of Physician’s Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator’s choice of protocol in patients with locally advanced or metastatic biliary tract cancer who have failed prior platinum-based chemotherapy and PD-1/PD-L1 antibody therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoToripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoIparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
The primary objective is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) combined with GemOX and lenvatinib as conversion therapy for Initially Potentially Resectable intrahepatic cholangiocarcinoma and gallbladder cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoVebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEnvafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Brief Summary The goal of this clinical trial is to test whether the combination of Envafolimab (an immunotherapy drug), chemotherapy (gemcitabine + cisplatin), and simvastatin can help treat advanced biliary tract cancer (BTC) that cannot be removed by surgery or has spread. The study will also evaluate the safety of this treatment combination. Key Questions Does the combination treatment help shrink tumors or slow cancer growth better than standard options? What side effects do participants experience with this treatment? What Will Participants Do? Receive Envafolimab (IV infusion) + gemcitabine/cisplatin (chemotherapy) + simvastatin (oral pill) every 3 weeks for up to 8 cycles (\~6 months). After 8 cycles, continue with Envafolimab + simvastatin alone every 4 weeks until cancer worsens or side effects become too severe. Undergo regular scans, blood tests, and clinic visits to monitor tumor response and safety.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPhase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin
A Phase 2 clinical trial protocol for evaluating the efficacy and safety of OBI-833/OBI-821, a carbohydrate-conjugate vaccine combined with an immune adjuvant, as maintenance therapy in combination with first-line gemcitabine and cisplatin chemotherapy for patients with Globo H-positive advanced biliary tract cancer. The study is designed as a single-arm trial with 30 patients who have achieved stable disease, partial response, or complete response after 3±1 months of initial chemotherapy. The primary endpoint is progression-free survival, with secondary endpoints including overall survival, tumor response, and safety profile. The treatment regimen involves subcutaneous injections of OBI-833/OBI-821 on a gradually decreasing frequency schedule for up to 80 weeks. The trial also includes exploratory objectives to assess immune responses and biomarkers. This study aims to address the unmet need for improved treatment options in advanced biliary tract cancer by leveraging the potential of immunotherapy targeting the Globo H antigen.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic cholangiocarcinoma or other biliary tract cancers after standard therapy. Part A determines safety, dose-limiting toxicities (DLTs), and the recommended phase 2 dose (RP2D) after reduced-intensity lymphodepletion. Part B evaluates preliminary anti-tumor activity, CAR-NK persistence, and biomarker-response associations.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of BL-M07D1 Versus Physician’s Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after platinum-containing chemotherapy failure.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoStudy of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or metastatic biliary tract cancer whose tumors carry EGFR mutations. Participants will be randomly assigned to receive either the experimental combination (becotatug vedotin + pucotenlimab + gemcitabine + cisplatin) or the control combination (pucotenlimab + gemcitabine + cisplatin). The main goal is to see if the experimental group has a higher objective response rate (tumor shrinkage rate). This is a randomized, controlled, open-label, multicenter study led by Sir Run Run Shaw Hospital, Zhejiang University, with Dr. Chen Mingyu as the principal investigator.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSurufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
This study is a single-arm, open-arm, single-center clinical study to explore the efficacy and safety of HAIC in combination with Surufatinib and Toripalimab in patients with inoperable or metastatic intrahepatic cholangiocarcinoma. The study was divided into three stages: screening period, treatment period and follow-up period. During the treatment period, the tumor status was evaluated by imaging every 6 weeks (±7 days), and the efficacy was changed to every 8 weeks (±7 days) after 12 weeks until the disease progressed (RECIST 1.1) or death (during the treatment of the patient) or toxicity became intolerable. The tumor treatment status and survival status after the disease progression were recorded. Safety outcome measures included AE, changes in laboratory test values, vital signs and electrocardiogram changes.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea. Tissue-based genomic profiling is often limited due to the anatomical challenges of tumor biopsy and insufficient DNA quality. ctDNA analysis offers a minimally invasive alternative for identifying actionable genetic alterations, including Fibroblast Growth Factor Receptor 2 (FGFR2) fusions, Isocitrate Dehydrogenase 1 (IDH1) mutations, and Human Epidermal Growth Factor Receptor 2 (HER2) amplifications. The study will recruit 100 patients across 11 institutions and assess the concordance between ctDNA and tissue genomic profiling, as well as the clinical relevance of ctDNA in predicting treatment outcomes and prognosis.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer that are resistant to Taxanes. Subjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment. If subject does not develop disease progression , the subject continues treatment until disease progression (RECIST 1.1) or develops an intolerable toxicity, initiation of a new anti-cancer drug, withdrawal from the study, death, or loss of follow-up. This is a single-arm, small-sample clinical study with the primary efficacy goal of objective remission rate (ORR). The parameters of the trial were set: assuming a class I error of 0.025 unilaterally, power=90%, and a 15% improvement in ORR for objective remission rate, a total of 20 subjects would be required, and a total of 25 would be required for enrolment, taking into account a 20% shedding.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info